Nanomedicine News RSS Feed - Nanomedicine

Tekmira Preparing Complete Response to FDA for TKM-Ebola Phase I Clinical Hold

Tekmira Preparing Complete Response to FDA for TKM-Ebola Phase I Clinical Hold

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced an update on the TKM-Ebola Phase I clinical hold. The Company has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) and is preparing a Complete Response to the Agency. The Company anticipates this matter will be resolved by Q4, 2014. [More]
Celator Broadens Application of CombiPlex Platform and CPX-351 for AML Treatment

Celator Broadens Application of CombiPlex Platform and CPX-351 for AML Treatment

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today will present updates on its lead candidate CPX-351 and CombiPlex® technology platform at its Analyst Day meeting for analysts and investors. [More]
Researchers Employ Magnetized Carbon Nanotubes to Extract Biomolecules from Live Cells

Researchers Employ Magnetized Carbon Nanotubes to Extract Biomolecules from Live Cells

University of Houston researchers have devised a new method for extracting molecules from live cells without disrupting cell development, work that could provide new avenues for the diagnosis of cancer and other diseases. [More]
Improved Method for Exact Dosing of Heavy Ion Irradiation to Treat Cancer

Improved Method for Exact Dosing of Heavy Ion Irradiation to Treat Cancer

PTB has developed a method for the more exact dosing of heavy ion irradiation in the case of cancer [More]
New Self-Assembling Nanoparticle Enables Early Diagnosis of Cancer

New Self-Assembling Nanoparticle Enables Early Diagnosis of Cancer

Scientists have designed a new self-assembling nanoparticle that targets tumours, to help doctors diagnose cancer earlier. [More]
NanoViricides Presents FluCide Data at 3rd Annual Influenza Research and Development Conference

NanoViricides Presents FluCide Data at 3rd Annual Influenza Research and Development Conference

NanoViricides, Inc. reports that its President, Dr. Anil Diwan, was invited to present the FluCide™ data at the 3rd Annual Influenza Research and Development Conference on Friday, July 11, at 0850 am. [More]
Thomson Reuters Honors UNM Cancer Center Scientist on 2014 List of ‘Highly-Cited Researchers’

Thomson Reuters Honors UNM Cancer Center Scientist on 2014 List of ‘Highly-Cited Researchers’

Of the 7 billion people in the world, Thomson Reuters, chose only 3,200 for its recent list of “The World’s Most Influential Scientific Minds.” Vittorio Cristini, PhD, of the University of New Mexico Cancer Center, places among them. Dr. Cristini says, “I never expected this. It is truly amazing. I’m thrilled.” [More]
Market Opportunities Report on Poorly Soluble and Poorly Permeable Drugs

Market Opportunities Report on Poorly Soluble and Poorly Permeable Drugs

Poor bioavailability is a major reason for compounds to fail in preclinical development. Technology Catalysts International (TCI), a leading global pharmaceutical consulting firm, has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds. [More]
Novel Nanotech Microchip for Diagnosis of Type-1 Diabetes

Novel Nanotech Microchip for Diagnosis of Type-1 Diabetes

An inexpensive, portable, microchip-based test for diagnosing type-1 diabetes could improve patient care worldwide and help researchers better understand the disease, according to the device's inventors at the Stanford University School of Medicine. [More]
Photoacoustic Tomography Illuminates ‘Nanojuice’ in the Intestine

Photoacoustic Tomography Illuminates ‘Nanojuice’ in the Intestine

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots, but each suffers limitations. [More]